LEXINGTON, Mass., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (“TGF-ß”) family of proteins, today reported financial results for the quarter ended June 30, 2025.
Related Questions
Did Keros Therapeutics provide any updates on its clinical trial milestones or regulatory timelines for its TGF‑β‑targeted therapeutics?
What macro or sector trends could amplify or mitigate the impact of Keros Therapeutics' Q2 results on the broader biotech market?
Are there any potential risks or upside catalysts highlighted in the release that could affect the stock's volatility?
How might the sentiment score of 10 influence short‑term trading sentiment and momentum in the stock?
What were the revenue and net loss figures for Q2 2025, and how do they compare to the previous quarter and the same quarter in 2024?
Did the earnings release include any guidance for Q3 2025 or the full‑year 2025, and what are the implications for analysts' forecasts?
Are there any notable changes in the company's R&D expenses or partnership activities that could impact future growth prospects?
Will the Q2 2025 earnings beat analyst consensus estimates and how will that affect KROS's share price?
What is the market's perception of Keros Therapeutic's competitive positioning relative to other TGF‑β pathway drug developers?
How does the company's cash runway and capital allocation plan look after the reported Q2 results?